Anlon Healthcare Q4 and FY26: Growth, acquisitions, and a shifting revenue mix

FY26 total income was INR 172.22 crore, EBITDA was INR 47.77 crore (27.74% margin), and PAT was INR 29.09 crore (16.89% margin) as per the income statement in the presentation.

Q4FY26 total income was INR 50.90 crore versus INR 48.97 crore in Q4FY25. EBITDA was INR 15.31 crore versus INR 17.23 crore, and PAT was INR 11.07 crore versus INR 16.65 crore, indicating lower quarterly profitability year-on-year.

For FY26, the presentation shows APIs at 71.24%, Pharmaceutical Intermediates at 26.37%, Nutraceuticals at 1.93%, and Others at 0.46%.

The presentation cites acquisition of 67.48% of Apiqo Organics Pvt. Ltd. (completed) for INR 5.40 crore to strengthen backward integration, and 56.67% of Bizotic Lifescience Pvt. Ltd. (SPA executed; completion expected in about 3 months) for INR 3.79 crore to accelerate capacity expansion.

The company states it has filed 21 DMFs. It mentions CEP approval from EDQM for Ketoprofen and filings/approvals in process with ANVISA (Brazil) and NMPA (China) for Loxoprofen Sodium Dihydrate, plus DMF submissions in progress for Ketoprofen in the USA and Dexketoprofen Trometamol in key European jurisdictions.

The presentation states existing Anlon capacity of 400 MTPA, incremental capacity of 700-800 MTPA from Apiqo, and 300-400 MTPA from Bizotic, leading to total projected capacity of 1,400-1,600 MTPA by FY26. A separate outlook slide also mentions 14,000-16,000 MTPA post expansion without reconciliation.

As per the presentation, the BSE share price was INR 14.23 with market capitalization of INR 756.32 crore, 52-week high INR 17.20 and low INR 8.70. Shareholding shows Promoter and Promoter Group at 52.68% and Public at 47.32%.